MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression

Blood

Volumn 117, Issue 24, 2011, Pages 6627-6637

  Desjobert, Cécile ^a   Renalier, Marie Hélène ^b,f   Bergalet, Julie ^a   Dejean, Emilie ^a   Joseph, Nicole ^b   Kruczynski, Anna ^c   Soulier, Jean ^d,e   Espinos, Estelle ^a,f   Meggetto, Fabienne ^a   Cavaillé, Jérome ^b   Delsol, Georges ^a,f,g   Lamant, Laurence ^a,f,g  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b CNRS   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITÉ PARIS DIDEROT   (France)

^f UNIVERSITÉ DE TOULOUSE   (France)

^g CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; HYBRID PROTEIN; MICRORNA; MICRORNA 29A; NUCLEOPHOSMIN; PROTEIN BCL 2; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; FIBROBLAST; GENE OVEREXPRESSION; GENE REPRESSION; LARGE CELL LYMPHOMA; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TRANSGENIC MOUSE; TUMOR GROWTH;

EID: 79959213619     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-301994     Document Type: Article

References (44)

1. Delsol GFB, Mûller-hermelink HK, Campo E, et al. Anaplastic Large Cell Lymphoma, ALK-Positive. Lyon, France: IARC Press; 2008.
2. Mason DYHN, Delsol G, Stein H, et al. Anaplastic Large Cell Lymphoma, ALK-Negative. Lyon: IARC Press; 2008.
3. Sarris AH, Luthra R, Papadimitracopoulou V, et al. Amplification of genomic DNAdemonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood. 1996;88(5):1771-1779. (Pubitemid 26307074)
4. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995;86(5):1954-1960.
5. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23.
6. Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci. 2001; 26(1):61-66. (Pubitemid 32124712)
7. Craig RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia. 2002;16(4):444-454. (Pubitemid 34449724)
8. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood. 1997;89(2):630-643. (Pubitemid 27051700)
9. Schlaifer D, Krajewski S, Galoin S, et al. Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection. Am J Pathol. 1996;149(1):177-185. (Pubitemid 26230989)
10. Rassidakis GZ, Lai R, McDonnell TJ, Cabanillas F, Sarris AH, Medeiros LJ. Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. Am J Pathol. 2002;160(6):2309-2310. (Pubitemid 34663421)
11. Rust R, Harms G, Blokzijl T, et al. High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma. J Clin Pathol. 2005; 58(5):520-524. (Pubitemid 40646874)
12. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci. 2009; 66(8):1326-1336.
13. Michels J, Johnson PW, Packham G. Mcl-1. Int J Biochem Cell Biol. 2005;37(2):267-271. (Pubitemid 39330187)
14. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20(5):515-524. (Pubitemid 43345317)
15. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102-114.
16. Kluiver J, Kroesen BJ, Poppema S, van den Berg A. The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. Leukemia. 2006;20(11): 1931-1936.
17. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793-1801. (Pubitemid 41549891)
18. Garzon R, Heaphy CE, Havelange V, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009;114(26):5331-5341.
19. Zhao JJ, Lin J, Lwin T, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010; 115(13):2630-2639.
20. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189-198. (Pubitemid 43357945)
21. Xiong Y, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2010;51(3):836-845.
22. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065-7070. (Pubitemid 41161233)
23. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007;26(42):6133-6140. (Pubitemid 47414372)
24. Merkel O, Hamacher F, Laimer D, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A. 2010;107(37):16228- 16233.
25. Giuriato S, Faumont N, Bousquet E, et al. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biol Ther. 2007;6(8):1318-1323. (Pubitemid 351590389)
26. Giuriato S, Foisseau M, Dejean E, et al. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK+ early B-cell lymphoma/ leukemia. Blood. 2010;115(20):4061-4070.
27. Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood. 1988;72(1):234-240.
28. Epstein AL, Kaplan HS. Biology of the human malignant lymphomas. I. Establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas. Cancer. 1974;34(6): 1851-1872.
29. Lamant L, Espinos E, Duplantier M, et al. Establishment of a novel anaplastic large-cell lymphoma-cell line (COST) from a 'small-cell variant' of ALCL. Leukemia. 2004;18(10):1693-1698.
30. del Mistro A, Leszl A, Bertorelle R, et al. A CD30-positive T cell line established from an aggressive anaplastic large cell lymphoma, originally diagnosed as Hodgkin's disease. Leukemia. 1994; 8(7):1214-1219. (Pubitemid 24224528)
31. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6(12 pt 1):3314-3322.
32. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle. 2006;5(19):2220-2222. (Pubitemid 44546557)
33. Saito Y, Suzuki H, Tsugawa H, et al. Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with down-regulation of Mcl-1 in human gastric cancer cells. Oncogene. 2009;28(30):2738-2744.
34. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009; 69(10):4443-4453.
35. Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 2009;125(11):2737-2743.
36. Michels J, O'Neill JW, Dallman CL, et al. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene. 2004; 23(28):4818-4827. (Pubitemid 38932154)
37. Amin HM, McDonnell TJ, Ma Y, et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK+ anaplastic large cell lymphoma. Oncogene. 2004;23(32):5426-5434. (Pubitemid 39044053)
38. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006;66(13):6589-6597. (Pubitemid 44085614)
39. Wei LH, Kuo ML, Chen CA, et al. The antiapoptotic role of interleukin-6 in human cervical cancer is mediated by upregulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene. 2001;20(41):5799-5809.
40. Hwang HW, Wentzel EA, Mendell JT. A hexanucleotide element directs microRNA nuclear import. Science. 2007;315(5808):97-100. (Pubitemid 46196987)
41. Calin GA, Croce CM. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood. 2009;114(23):4761-4770.
42. Valeri N, Vannini I, Fanini F, Calore F, Adair B, Fabbri M. Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome. 2009;20(9-10):573-580.
43. Ambrogio C, Martinengo C, Voena C, et al. NPMALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 2009;69(22):8611-8619.
44. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007;104(40):15805-15810. (Pubitemid 350035380)